日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer

新发转移性乳腺癌的疾病表现和治疗启动方面的差异

Freeman, Jincong Q; Ravichandran, Apoorva; Poland, Sarah; Hennessy, Maeve A; Guo, Wenji; Nanda, Rita

Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression

单细胞分析揭示了高糖皮质激素受体表达的三阴性乳腺癌中富含调节性T细胞(Treg)而自然杀伤细胞(NK)耗竭的免疫微环境

Behar, Joshua; Shiang, Christine; Dolcen, Deniz Nesli; Bennett, Lynda B; DeVilbiss, Andrew W; Matossian, Margarite D; Chan, Isaac S; Nanda, Rita; Conzen, Suzanne D; Lafin, John T

K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy

基于K均值聚类的定量超快速动态对比增强磁共振成像分析预测乳腺癌对新辅助化疗的反应

Ren, Zhen; Fan, Xiaobing; Medved, Milica; Howard, Frederick M; Nanda, Rita; Abe, Hiroyuki; Kulkarni, Kirti; Biernacka, Anna; Chen, Nan; Karczmar, Gregory S

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial

在 I-SPY 临床试验中识别与后续免疫相关不良事件相关的早期症状

Basu, Amrita; Umashankar, Saumya; Melisko, Michelle; Roy, Ritu; Yau, Christina; Pusztai, Lajos; Chien, A Jo; Liu, Minetta; Han, Hyo; Soliman, Hatem; Isaacs, Claudine; Shatsky, Rebecca; Stringer-Reasor, Erica; Robinson, Patricia; Yeung, Kay; Kalinsky, Kevin; Thomas, Alexandra; Philip, Errol; Musthafa, Mina; Hirst, Gillian; Asare, Adam; DeMichele, Angela; Van't Veer, Laura; Yee, Douglas; Hylton, Nola; Olshen, Adam; Perlmutter, Jane; Cohen, Ronald N; Quandt, Zoe; Esserman, Laura; Hershman, Dawn; Rugo, Hope; Nanda, Rita

Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer

重新思考雌激素受体低下乳腺癌的治疗重点

Freeman, Jincong Q; Nanda, Rita; Howard, Frederick M

Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer

儿童癌症幸存者女性在再次罹患乳腺癌后的治疗、毒性和死亡率

Im, Cindy; Hasan, Hasibul; Stene, Emily; Monick, Sarah; Rader, Ryan K; Sheade, Jori; Wolfe, Heather; Lu, Zhanni; Spector, Logan G; McDonald, Aaron J; Nolan, Vikki; Arnold, Michael A; Conces, Miriam R; Moskowitz, Chaya S; Henderson, Tara O; Robison, Leslie L; Armstrong, Gregory T; Yasui, Yutaka; Nanda, Rita; Oeffinger, Kevin C; Neglia, Joseph P; Blaes, Anne; Turcotte, Lucie M

Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers

激素受体阳性、HER2阴性/MammaPrint高表达2型乳腺癌与三阴性乳腺癌非常相似。

Rios-Hoyo, Alejandro; Xiong, Kaitlyn; Dai, Jiawei; Yau, Christina; Marczyk, Michal; Garcia-Milian, Rolando; Wolf, Denise M; Huppert, Laura A; Nanda, Rita; Hirst, Gillian L; Cobain, Erin F; van 't Veer, Laura J; Esserman, Laura J; Pusztai, Lajos

Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US

美国三阴性乳腺癌免疫疗法应用趋势及差异

Freeman, Jincong Q; Huo, Dezheng; Shubeck, Sarah P; Chen, Nan; Yarlagadda, Sudha R; Nanda, Rita; Howard, Frederick M

Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial

RxPONDER试验后辅助化疗在激素受体阳性、ERBB2阴性乳腺癌中的应用

Freeman, Jincong Q; Saha, Poornima; Peiffer, Daniel S; Chen, Nan; Shubeck, Sarah P; Yarlagadda, Sudha R; Nanda, Rita; Huo, Dezheng; Howard, Frederick M

Clinical Trial Discussion and Participation in a Breast Cancer Cohort by Race and Ethnicity

按种族和民族划分的乳腺癌队列临床试验讨论和参与情况

Chen, Nan; Freeman, Jincong Q; Zhao, Fangyuan; Goldberg, Leah; Yarlagadda, Sudha R; Terman, Elizabeth; Huo, Dezheng; Nanda, Rita